stockrowGlaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
Follow GKOS
Alert me
Glaukos Corporation (GKOS) Total debt
Glaukos Corporation's total debt at the end of fiscal 2025 was $68.1M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $66.9M. Over the past ten years it has ranged from $9.7M (fiscal 2015) to $353.6M (fiscal 2022); the current reading is higher than 38% of that period. Glaukos Corporation ranks 44th of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $68.1M | (1.95%) |
| FY2024 | $69.5M | (80.34%) |
| FY2023 | $353.3M | (0.07%) |
| FY2022 | $353.6M | 0.24% |
| FY2021 | $352.7M | 41.03% |
| FY2020 | $250.1M | 328.01% |
| FY2019 | $58.4M | 502.67% |
| FY2015 | $9.7M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $66.9M | (0.62%) |
| Jun 2026 | $67.3M | (0.59%) |
| Mar 2026 | $67.7M | (0.54%) |
| Dec 2025 | $68.1M | (0.52%) |
| 34 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ZBH Zimmer Biomet Holdings, Inc. compare | $7.5B |
| SNN Smith & Nephew SNATS, Inc. compare | $3.2B |
| BRKR Bruker Corporation compare | $1.7B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $1.2B |
| BIO Bio-Rad Laboratories, Inc. compare | $1.2B |
| PODD Insulet Corporation compare | $962.1M |
| GMED Globus Medical, Inc. compare | $443.4M |
| GKOS Glaukos Corporation | $66.9M |
| PEN Penumbra, Inc. compare | $19.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on GKOS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement